Influenza and COVID-19 vaccine is a combined messenger RNA vaccine (mRNA) for protection against influenza and COVID-19. It contains mRNA molecules that encode the full-length, membrane-bound hemagglutinin glycoproteins of seasonal influenza virus types A (H1N1 and H3N2) and B (Victoria lineage), as well as parts of the SARS-CoV-2 spike protein, namely the membrane-bound, linked N-terminal domain and the receptor-binding domain. It is the first combined vaccine against influenza and COVID-19.
The most common side effects include injection site pain, fatigue (tiredness), myalgia (muscle pain), arthralgia (joint pain), headache, chills, lymphadenopathy (swollen lymph nodes), nausea/vomiting, and pyrexia (fever).
Mcombriax was authorized for medical use in the European Union in April 2026.
Medical uses The combined influenza vaccine and COVID-19 vaccine is used to provide active immunization for the prevention of influenza disease caused by influenza virus subtypes A and type B; and COVID-19 caused by the SARS-CoV-2 virus.
Society and culture Legal status In February 2026, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Mcombriax, intended for the prevention of influenza disease and COVID-19 caused by SARS-CoV-2 in adults aged 50 years and older. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged. Mcombriax was authorized for medical use in the European Union in April 2026.
References
Further reading